Non-Hodgkin's Lymphoma Articles | Page 2

Goy Lends Insight on Acalabrutinib and Ibrutinib in MCL
Andre Goy, MD, discusses the excitement surrounding acalabrutinib, as well as emerging ibrutinib combination strategies for the treatment of patients with mantle cell lymphoma.
CLL Expert Explains Latest Treatment Developments in the Field
Neil E. Kay, MD, discusses the available options and sequencing challenges for patients with relapsed/refractory chronic lymphocytic leukemia, as well as next steps for advancing outcomes for this patient population.
Ibrutinib, Venetoclax, and Obinutuzumab Triplet Safe, Effective as Initial CLL Therapy
Kerry A. Rogers, MD, discusses the promise of the obinutuzumab, ibrutinib, and venetoclax triplet as a first-line treatment for patients with chronic lymphocytic leukemia.
Flinn Sheds Light on Advances in MCL and Other Lymphomas
Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.
Davids Discusses Frontline CLL Combo of Ibrutinib Plus Chemoimmunotherapy
Matthew S. Davids, MD, discusses the key results of ibrutinib (Imbruvica) with standard frontline chemoimmunotherapy in CLL. 
Gene Expression Model Predicts PFS in Follicular Lymphoma
A “robust” 23-gene expression-based model successfully predicted progression-free survival for patients with follicular lymphoma enrolled in the phase III randomized PRIMA trial.
Flinn Highlights Emerging Combinations in CLL
Ian W. Flinn, MD, discusses ongoing advances with emerging combination regimens in chronic lymphocytic leukemia.
Ibrutinib Continues to Demonstrate Effectiveness in MCL
Brad S. Kahl, MD, discusses the latest data for ibrutinib and highlights emerging treatments in mantle cell lymphoma. 
Umbralisib Shows Early Promise in CLL and Lymphoma
The PI3K-delta inhibitor umbralisib (TGR-1202) induced an objective response rate of 37% in patients with relapsed/refractory lymphoma or chronic lymphocytic leukemia.
Combinations Explored in MCL After Second BTK Inhibitor Approval
Brian T. Hill, MD, PhD, discusses acalabrutinib and ibrutinib’s efficacy in patients with mantle cell lymphoma and highlights emerging novel strategies in the treatment landscape.
Publication Bottom Border
Border Publication